Evogene Forms Joint Initiative with Tel Aviv University to Boost AI-Driven Drug Discovery
EVGN is trading near its 52-week low of $0.37 (15% above the low) on light trading volume (0.1× avg).
Summary
Evogene announced a joint initiative with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to accelerate AI-driven small-molecule drug discovery. This collaboration combines BCDD's experimental infrastructure with Evogene's ChemPass AI™ computational chemistry engine to bridge the gap between academic biological insights and drug candidate development. The partnership aims to broaden Evogene's pipeline of drug candidates, following recent financial challenges including a wider net loss and a dilutive ATM offering. This strategic move leverages Evogene's core AI technology to source and develop new therapeutic programs.
At the time of this announcement, EVGN was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.37 to $1.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.